October 11, 2022
Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years old
September 5, 2022
Late-Breaking Dupixent® (Dupilumab) Data at Ers 2022 Show Consistent Efficacy and Safety Profile for up to Two Years in Children Aged 6 to 11 Years With Moderate-To-Severe Asthma
August 30, 2022
Press Release: FDA Grants Priority Review to Efanesoctocog Alfa for People With Hemophilia A
No current content.